| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis CAMMS223 Trial Investigators New England Journal of Medicine 359 (17), 1786-1801, 2008 | 1167 | 2008 |
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ... Journal of neurology 253, 98-108, 2006 | 599 | 2006 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 461 | 2019 |
| IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) JL Jones, CL Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, ... The Journal of clinical investigation 119 (7), 2052-2061, 2009 | 343 | 2009 |
| Cross-tissue immune cell analysis reveals tissue-specific features in humans C Domínguez Conde, C Xu, LB Jarvis, DB Rainbow, SB Wells, T Gomes, ... Science 376 (6594), eabl5197, 2022 | 337 | 2022 |
| Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis AL Cox, SAJ Thompson, JL Jones, VH Robertson, G Hale, H Waldmann, ... European journal of immunology 35 (11), 3332-3342, 2005 | 328 | 2005 |
| Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy O Tuohy, L Costelloe, G Hill-Cawthorne, I Bjornson, K Harding, ... Journal of Neurology, Neurosurgery & Psychiatry 86 (2), 208-215, 2015 | 269 | 2015 |
| Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ... Neurology 77 (6), 573-579, 2011 | 256 | 2011 |
| B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles Journal of clinical immunology 30, 99-105, 2010 | 254 | 2010 |
| Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation JL Jones, SAJ Thompson, P Loh, JL Davies, OC Tuohy, AJ Curry, ... Proceedings of the National Academy of Sciences 110 (50), 20200-20205, 2013 | 228 | 2013 |
| Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple … SV Abrahamsson, DF Angelini, AN Dubinsky, E Morel, U Oh, JL Jones, ... Brain 136 (9), 2888-2903, 2013 | 214 | 2013 |
| Distinct microbial and immune niches of the human colon KR James, T Gomes, R Elmentaite, N Kumar, EL Gulliver, HW King, ... Nature Immunology 21 (3), 343-353, 2020 | 211 | 2020 |
| Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis GA Hill-Cawthorne, T Button, O Tuohy, JL Jones, K May, J Somerfield, ... Journal of Neurology, Neurosurgery & Psychiatry 83 (3), 298-304, 2012 | 209 | 2012 |
| Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity JL Jones, JM Anderson, CL Phuah, EJ Fox, K Selmaj, D Margolin, ... Brain 133 (8), 2232-2247, 2010 | 202 | 2010 |
| Immune competence after alemtuzumab treatment of multiple sclerosis CL McCarthy, O Tuohy, DAS Compston, DS Kumararatne, AJ Coles, ... Neurology 81 (10), 872-876, 2013 | 143 | 2013 |
| The immunological response to traumatic brain injury EJ Needham, A Helmy, ER Zanier, JL Jones, AJ Coles, DK Menon Journal of neuroimmunology 332, 112-125, 2019 | 128 | 2019 |
| Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes MS Zandi, RW Paterson, MA Ellul, L Jacobson, A Al-Diwani, JL Jones, ... Journal of Neurology, Neurosurgery & Psychiatry 86 (7), 708-713, 2015 | 125 | 2015 |
| Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis L Costelloe, J Jones, A Coles Expert review of neurotherapeutics 12 (3), 335-341, 2012 | 115 | 2012 |
| Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy EA Marsh, CL Hirst, JG Llewelyn, MD Cossburn, MM Reilly, A Krishnan, ... Journal of neurology 257, 913-919, 2010 | 96 | 2010 |
| Oligodendrocyte susceptibility to injury by T-cell perforin. NJ Scolding, J Jones, DA Compston, BP Morgan Immunology 70 (1), 6, 1990 | 76 | 1990 |
